About US
Contact us
-
Jury sides with Merck and its execs in gender-bias caseMerck & Co. ($MRK) won the day in a gender discrimination suit on Tuesday, as a federal jury found that former employee Kerri Colicchio failed to prove she was discriminated against because of h2015/6/4
-
Merck's 'landmark' Zetia data hits NEJM, giving a boost to all LDL-fighting medsThe nitty-gritty on Merck & Co.'s ($MRK)Zetiaoutcomes trial is now revealed--and it's not just good news for the cholesterol-fighting drug and its combo-pill sister Vytorin. It's good for all high2015/6/4
-
Roche, Novartis and Bayer snag NICE OKsThe U.K.'s cost-effectiveness gatekeeper, the National Institute for Health and Care Excellence (NICE), has bestowed its favor on a crop of new drugs, granting nods to contenders from Roche ($RHHBY),2015/6/3
-
Tumor tests for immuno-oncology drugs need some work, cancer experts sayDrugmakers are quick to cite results from tests for new immuno-oncology meds, with companies such as Bristol-Myers Squibb ($BMY), Merck ($MRK), Roche ($RHHBY) and Pfizer ($PFE) screening for biomarker2015/6/3
-
Top oncologist joins chorus of pricing critics in high-profile ASCO speechPharma types are getting a wee bit defensive about critics' attacks on cancer drug prices, if response toFiercePharma's recent coverage is any indication. But the criticism just keeps on coming, even2015/6/2
-
Look for orphan drugs to keep fueling M&A, Moody's saysOrphan drugsare attractive to make thanks to premium pricing prospects, limited competition and regulatory perks. But those factors also make them attractive to buy, and they'll continue to spur M&2015/6/2
-
New standout Imbruvica data bode well for market expansion in CLLCHICAGO--Johnson & Johnson ($JNJ) and AbbVie's ($ABBV)Imbruvicahas already shown in one Phase III study that it can extend progression-free survival in patients with previously treated chronic lym2015/6/1
-
Adding Opdivo to Yervoy ups melanoma treatment efficacy--but it ups rate of serious side effects, tooCHICAGO--The data on Bristol-Myers Squibb's ($BMY) hot new immunotherapyOpdivokept rolling out Sunday at ASCO, showing that combining the drug with fellow Bristol cancer-fighterYervoyproved more effec2015/6/1
-
WSJ: FBI probes J&J over morcellator safety risksHow much did Johnson & Johnson ($JNJ) know about the risks of power morcellators--now suspended on safety concerns--before it pulled them from the market last year? That's the subject of a new inv2015/5/29
-
How well paid are pharma execs? Best in healthcare, survey showsWe know how executive pay in pharma tends to shake out: U.S. corporate chiefs get paid more than their European counterparts; execs at big-cap drugmakers reliably earn $15 million or more; and these d2015/5/29